A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ALKS 33-BUP Administration in Subjects With Major Depressive Disorder

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ALKS 33-BUP Administration in Subjects With Major Depressive Disorder

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Oct 2014

At a glance

  • Drugs Buprenorphine/samidorphan (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Alkermes plc
  • Most Recent Events

    • 29 May 2012 Additional trial results presented according to an Alkermes media release.
    • 04 Jan 2012 Based on the results of this trial, Alkermes has accelerated the start of the phase II study of buprenorphine/samidorphan for major depressive disorder, according to a company reported media release [see separate trial profile 700211641].
    • 18 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top